

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> <b>A01N 1/00, 1/02</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/45010</b> <b>(43) International Publication Date:</b> 4 December 1997 (04.12.97)
<b>(21) International Application Number:</b> PCT/US97/09207 <b>(22) International Filing Date:</b> 29 May 1997 (29.05.97)  <b>(30) Priority Data:</b> 60/018,638                      29 May 1996 (29.05.96)                      US  <b>(71) Applicant (for all designated States except US):</b> UNIVERSAL PRESERVATION TECHNOLOGIES, INC. [US/US]; Building 1, Suite 204, 625 Panorama Trail, Rochester, NY 14625 (US).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> BRONSHTEIN, Victor [US/US]; 76 Lost Mountain Trail, Rochester, NY 14625 (US).  <b>(74) Agents:</b> JOHNSON, Barbara, E. et al.; Webb Ziesenheim Bruening Logsdon Orkin & Hanson, P.C., 700 Koppers Building, 436 Seventh Avenue, Pittsburgh, PA 15219-1818 (US).		<b>(81) Designated States:</b> AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> LOADING AND UNLOADING OF PERMEATING PROTECTANTS FOR CELL, TISSUE, AND ORGAN CRYOPRESERVATION BY VITRIFICATION  <b>(57) Abstract</b>  The present invention is directed to a method for cryopreserving a biological sample, including gradually or stepwise loading the sample with permeating protectant by contacting the sample with solutions including the protectant and a non-permeating co-solute that limits the amount of protectant that penetrates into cells of the biological specimen. The method further includes the gradual or step of unloading (rehydration) of the sample by contacting the sample with one or more rehydration solutions having progressively lower concentrations of both the protectant and co-solute, such that the protectant is removed from the cells of the sample. Concentration of the co-solute during loading and unloading should be at maximum value that still does not damage the sample at room and subzero temperatures.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**LOADING AND UNLOADING OF PERMEATING PROTECTANTS FOR CELL,  
TISSUE, AND ORGAN CRYOPRESERVATION BY VITRIFICATION**

**1. Field of Invention**

The present invention relates to non-toxic  
5 loading and unloading of permeating protectants that is  
required for the cryopreservation of biological specimens  
(cells and multicellular specimens) by vitrification, or  
for other purposes.

**2. Background of the Invention**

10 Conventional low temperature preservation of  
biological specimens by freezing is not uncommon. However,  
the strong damaging action of ice crystallization limits  
application of cryogenic methods to the cryopreservation of  
cells and multicellular specimens. Vitrification is an  
15 alternative approach to cryopreservation that utilizes  
solidification of samples during cooling, without formation  
of ice crystals (Fahy et al., 1984). There is currently a  
need for a reliable method of cell (erythrocyte, stem  
cells, sperm, etc.) and multicellular specimens (kidney,  
20 heart, etc.) cryopreservation by vitrification. However,  
the development of these methods was not possible because  
of several generally accepted misconceptions and  
deficiencies of the prior art that have been addressed by  
the inventor (Bronstein, 1995). The following are some  
25 misconceptions and deficiencies of prior art.

**Effects of Dehydration**

Ice formation at low temperatures can be avoided  
only if samples are sufficiently dehydrated. Dehydration,  
however, is also known as a common cell damaging factor.  
30 The damaging effect of the dehydration increases with  
increasing concentration of vitrification solution and  
depends strongly on whether the vitrification solution  
contains permeating protectants such as dimethylsulfoxide  
(DMSO), ethylene glycol (EG), propylene glycol, glycerol,  
35 etc. For example, cells normally cannot survive  
equilibration in solutions containing only non-permeating  
solutes in concentrations greater than 1 mol/l. However,  
many types of cells can easily tolerate equilibration in

solutions containing permeating protectants in much higher concentrations. This is because penetration of protectants protects cells against dehydration damage.

Here, it is important to note that dehydration  
5 does not mean decrease in the cell volume, which actually may be very damaging (Marymen, 1967, 1970). The term dehydration means removal of water, or increase in the osmotic pressure. Erroneous use of this term has resulted in several misconceptions. For example, as described  
10 below, dehydration by itself is not a strong damaging factor. Dehydration may even be a protective factor, if performed according to the present invention.

Damage of cells during dehydration in concentrated solutions of non-permeating solutes is  
15 believed to be caused by hydration forces occurring between biological macromolecules and membranes when distances between them become small as a result of dehydration Bryant and Wolfe (1992). However, it is believed that loading of cells with permeating protectant protects against cell  
20 dehydration because intracellular protectant diminishes these forces. Therefore, some amount of intracellular protectants are required to protect cells during dehydration to high osmotic pressures. For this reason, it was proposed (Rall and Fahy, 1985) to equilibrate  
25 biological specimens in loading solutions of permeating protectants (dimethyl sulfoxide (DMSO), ethylene glycol (EG), propylene glycol, glycerol, etc.) prior to dehydration, in order to reduce the strong damaging, effect of dehydration. Using this approach, Rall and Fahy (1985)  
30 cryopreserved mouse embryos by vitrification. Unfortunately, the protective effect of loading significantly decreases with increasing time of equilibration in vitrification solution containing permeating protectants.

35 The approach of Rall and Fahy (1985) was successfully applied to a variety of specimens containing a small amount of cells. However, vitrification of larger

and more complex specimens (e.g., human kidney, heart, or liver) has not been achieved yet primarily because of the toxic effect of highly concentrated solutions containing permeating protectants. These concentrated solutions are  
5 needed to prevent ice formation in complex specimens during cooling and warming. Therefore, one should consider the dependence of cell injury on the time of equilibration in vitrification solution to better understand the mechanism(s) of toxicity. For successful preservation by  
10 vitrification, vitrification solution should more effectively diminish both ice formation in the cytosol and extracellular volumes, and toxic effects associated with equilibration (dehydration) of the specimen in concentrated vitrification solution.

15 Apparent Toxicity of Vitrification Solutions

Based on the general erroneous belief that intracellular protectants help to vitrify cytosol (Bronshtein, 1995), and the fact that some intracellular protectant is required to protect cells during dehydration,  
20 penetration of protectant inside cells may be considered as desirable. A negative aspect of this penetration, considered in the literature, is associated with direct chemical toxicity of protectants (Fahy et al., 1990). Because the toxicity is believed to be proportional to the  
25 concentration of protectants (not to the amount of protectants inside a cell), three basic approaches have been proposed (for details see review of Steponkus et al., 1992) to minimize the toxicity:

- 1) to use a mixture of different permeating  
30 protectants;
- 2) to add components that may act as "toxicity neutralizers"; or
- 3) to identify solutes that will form a glass at lower concentrations.

35 However, Fahy et al. (1990) found that biochemical studies of the toxicity to date have not met

the basic criteria required for demonstrating mechanisms of toxicity. This actually means that the direct chemical toxicity of typical permeating protectants (ethylene glycol, propylene glycol, glycerol and DMSO) is small. The  
5 inventor agrees with the conclusion of Fahy et al. (1990) that present concepts of protectant toxicity are in need of serious revision.

Recently, Langis and Steponkus (1990) demonstrated that survival of isolated rye protoplast  
10 following the dehydration step is a function of osmolarity rather than the concentration of vitrification solutions. Based on this observation, Steponkus et al. (1992) discussed an alternative strategy for formulating less toxic solutions with lower osmolarity.

15 As mentioned above, cells can tolerate dehydration in a very concentrated vitrification solution for several minutes if they have been loaded with permeating protectants. However, during longer equilibration times in vitrification solutions, cell  
20 survival decreases with increasing time of equilibration. Because loading of cells with permeating protectants protects against the injury that occurs after dehydration in vitrification solution in the case of short dehydration times, one may suggest that the injury depends primarily on  
25 osmolarity. However, because the concentration of intracellular protectant that is reached after dehydration increases with increasing osmolarity of vitrification solution, the existing experimental observations do not answer the question whether damage of dehydrated embryos is  
30 a result of the increased concentration of intracellular protectant or of the increase in osmotic pressure. In both cases, however, the question as to why the injury increases with dehydration time remains to be answered. It is also very important because the time required to complete  
35 dehydration of multicellular specimens can be substantially longer than that for individual cells.

The inventor's observations (Bronshteyn and Steponkus, 1994, Steponkus et al., 1994) suggest that a significant part of the apparent toxicity of ethylene glycol-based vitrification solution for loaded *Drosophila melanogaster* embryos is associated with ethylene glycol permeation (increase in mass of ethylene glycol inside embryos) rather than with chemical toxicity of intra-embryo ethylene glycol, or osmotic pressure of vitrification solution. The injurious effect of permeation of protectants during equilibration in vitrification solution was also demonstrated in the studies performed with mouse embryos (Zhu et al., 1993; Tachikawa et al., 1993; Kasai et al., 1990). This toxic effect is not related to the increase in intracellular osmotic pressure or biochemical toxicity of protectant because after water efflux from loaded cells, the osmotic pressure and concentration of protectant inside cells is approximately equal to that outside the cells.

The inventor believes (without any intention of being bound by the theory) that the actual act of permeation of protectants into the cell during loading of high protectant concentrations is a main cause of cell damage that occurs during subsequent unloading.

#### Kinetics of Protectant Permeation Inside Cells

After the classical work of Kedem and Katchalsky (1958), it was generally accepted that the thermodynamic force responsible for protectant permeation inside cells is proportional to the gradient (across cell membrane) in protectant concentration independent of the composition of vitrification solution. However, the inventor (Bronshteyn and Steponkus, 1994) found that amino acids (glycine and glutamic acid) and carbohydrates (sucrose and sorbitol) significantly diminished ethylene glycol permeation into *Drosophila melanogaster* embryos. The preventive effect of amino acids was impressive because 1 wt% of glutamic acid + 0.5 wt% glycine limited ethylene glycol permeation inside

embryos for up to 3 hours of equilibration in vitrification solution containing 42 wt% ethylene glycol. The preventive effect of carbohydrates was about four times smaller. These observations show that the approach of Kedem and Katchalsky (1958) ignored the effect of co-solutes on the chemical potential of protectants. Therefore, the model of Kedem and Katchalsky (1958) and qualitative conclusions obtained based on this model cannot be used to analyze and predict permeation of protectant inside cells during equilibration in a vitrification solution.

#### Interaction Between Protectants and Proteins

Timasheff (1993) criticized the belief that protectants form some sort of coating (a shell) that protects proteins from denaturation during cryopreservation. His criticism was based on the articles of Gekko and Timasheff (1981), Lee and Timasheff (1981), and other publications reporting that protectants excluded from the surface of proteins. The inventor (Bronshtein, 1995) submitted that the above conclusion of Timasheff and his co-workers is questionable for two reasons. First, the thermodynamic equilibrium in the dialysis experiments of Timasheff and his co-workers cannot be obtained if the hydrostatic pressure inside the dialysis bag is equal to the pressure outside the bag. Further, the suggestion that the effect of this difference in the hydrostatic pressures is negligible is wrong. Second, amino acids limit penetration of protectant into the cell by decreasing the chemical potential of protectant in the extracellular aqueous solution (Bronshteyn and Steponkus, 1994). Therefore, (without any intention of being bound by the theory) protectants adsorb at the surface of proteins and partially replace water molecules hydrating the proteins. The amount of water of hydration, that is replaced by molecules of protectant, at the protein surface increases with increasing concentration of protectant.



Crowe et al. (1990) suggested that freezing and dehydration may be different stress vectors because they found that stabilization of proteins during drying occurs because of an attraction between sugars and proteins. The inventor believes (without any intention of being bound by the theory) that vitrification of the solution ("shell") at the surface of proteins (and biological membranes) is a general mechanism of protection equally valid for freezing and desiccation.

10 Effects of Intracellular Protectants on the Stability of Intracellular Amorphous State at Low Temperatures

Steponkus et al. (1992) have shown that decreasing osmolarity of the vitrification solution allows one to decrease the damaging effect of dehydration in vitrification solution if the dehydration time is several minutes or less. However, to obtain cell survival after cryopreservation, one should successfully vitrify both the extracellular solution and the cytosol. For this reason, Steponkus et al. (1992) suggested that the better protectant for the loading step is one that allows stable vitrification of cytosol after dehydration in vitrification solution with lower osmolarity. This suggestion was a reflection of a general belief that the presence of protectants inside cells helps to vitrify cytosol. However, the inventor's recent studies (Bronshtein, in preparation) have shown that vitrification temperature of the maximum freeze dehydrated bovine serum albumin (BSA) solution is  $T_g = -20^{\circ}\text{C}$ . In these studies,  $T_g$  was estimated as a temperature of detectable onset of ice melting endotherm. Therefore,  $T_g$  in protein solutions is much higher than that in solutions of permeating protectants. This suggests that stability of dehydrated cytoplasm, that does not contain protectants, is much higher than that of solutions of permeative protectants with the same osmotic pressure. This agrees with observations (Steponkus et al., 1992; Langis and Steponkus, 1990) obtained for protoplasts

from acclimated rye leaves. They found that a protoplast loaded with ethylene glycol must be subjected to greater dehydration than those not loaded with ethylene glycol to achieve maximum survival after storage in liquid nitrogen.

5 The inventors Bronshteyn and Steponkus (1993) found that intraembryo freezing in non-loaded *Drosophila* embryos after dehydration in vitrification solution occurs at significantly lower temperatures compared to those loaded with 2.125 M ethylene glycol during cooling at 5°C/min.

10 Therefore, contrary to the conventional point of view, addition of low molecular weight protectants into cytoplasm decreases the stability of the cytoplasm.

It is therefore an object of the present invention to provide a non-toxic method for loading

15 (filling in with permeating protectants and simultaneous dehydration) of cells, multicellular tissues, organs, and organisms with high concentrations of permeating protectants (PA) for cryopreservation by vitrification. The method should allow for controlled permeation of

20 protectants into the samples during long-term contact of the samples with the vitrification solution. It is also an object of the present invention to provide a non-damaging cell method for subsequent unloading (washing the PAs out and rehydration) of the PA and reconstituting the preserved

25 biological samples, and to provide a rehydrating solution for use during unloading (rehydration). Both loading and unloading methods, vitrification and rehydration solutions, should allow for superior survival of the cryopreserved sample. These methods and solutions are based on theories

30 that are opposite to the prior art misconceptions described above.

#### SUMMARY OF THE INVENTION

The present invention is directed to a method for minimizing toxic effects of loading and unloading

35 biological specimens with permeating protectants. The method includes the steps of loading the sample by contacting the sample with a solution comprising a

permeating protectant and a non-permeating co-solute that limits the amount of the protectant that penetrates into cells of the biological specimen. According to the method, decreasing the ability of the protectant to enter cells of the biological specimen is achieved most effectively by adding non-penetrating co-solutes that effectively decrease the chemical potential of permeating protectants in the extracellular solution. The more co-solute that is added, the less amount of protectant penetrates into the cells; however, some minimum amount of protectant inside the cells is required to protect the cells against dehydration. For this reason, the concentration of the co-solutes that can be added is limited. The maximum concentration of co-solutes that can be added to the extracellular solution, to limit penetration of protectant inside cells, depends on the minimum amount of protectant required to protect cells against dehydration. The maximum concentration of co-solutes can be found experimentally for every specific combination of permeating protectants, osmotic pressure of the extracellular solution, and type of co-solute.

The method also includes gradual or stepwise loading (unloading) of permeating protectants with simultaneous increase (decrease) in concentration of permeating protectants and non-permeating co-solutes. For a given concentration of protectants, concentration of non-permeating co-solutes should be the maximum possible concentration that still does not damage cells.

Co-solutes that decrease the chemical potential of penetrating Protectants or protectants in aqueous solutions include, but are not limited to:

1. Amino acids: glycine, alanine, glutamic acid, proline, valine, hydroxy-1-proline, betaaminopropionic acid, aminobutyric acid, beta-aminocaproic acid, aminoisobutyric acid, N-methylglycine, norvaline, and others that are soluble in water in concentration greater than 0.1 mol/l, and derivatives of amino acids (sarcosine, iminodiacetic acid,

hydroxyethyl glycine, etc.) that are soluble in water in concentration  $>0.1$  mol/l.

2. Betaines: betaine and other betaines that are soluble in water in concentration greater than 0.1 mol/l.

3. Carbohydrates:

a) Monosaccharides (aldoses and ketoses): glyceraldehyde, lyxose, ribose, xylose, galactose, glucose, hexose, mannose, talose, heptose, dihydroxyacetone, pentulose, hexulose, heptulose, octulose, etc., and their derivatives;

b) Amino sugars: D-ribose, 3-amino-3-deoxy-, chitosamine, fucosamine, etc.;

c) Alditols and inositols: glycerol, erythritol, arabinitol, ribitol, mannitol, iditol, betitol, inositol, etc.;

d) Aldonic, uronic, and aldaric acids that are soluble in water in concentration  $>0.1$  mol/l; and

e) disaccharides and polysaccharides (sucrose, trehalose, etc.).

4. Sugar alcohols (sorbitol, etc.).

Amino acids most effectively decrease the chemical potential of permeating protectants in aqueous solutions.

The invention allows one to significantly increase concentrations of vitrification solution and the times of loading, cell equilibration in the vitrification solution, and unloading, without increasing cell damage. This allows one to solve many problems occurring during loading of organs with protectants and subsequent cooling by decreasing gradients of osmotic pressure within the sample. This is a very important matter, because if a portion of cells in the sample is less dehydrated it may freeze at low temperatures and be damaged.

Hydration of the cells after cryopreservation and washing out of protectant (unloading) is achieved by equilibration of the specimens (perfusion with, in the case

of organs) in solutions of the same protectant with lower osmotic pressures, but still containing the maximum concentration of the co-solutes (amino acids, betaines or carbohydrates) that do not damage cells. The change of  
5 concentration during unloading may be gradual or stepwise. This will speed up efflux of protectant and limit the increase of the cell's volume during rehydration. This is an important issue because the increase in cell volume, more than the initial cell volume, may damage the cells.

10 The statements above reflect the inventor's recent discoveries that protectants preferentially attract to the surface of proteins (Bronshtein, 1995), that amino acids and sugars decrease the chemical potential of glycerol, propylene glycol, ethylene glycol (Bronshteyn and  
15 Steponkus, 1994) and other permeating protectants, that the toxicity of protectants increases with increasing mass of protectants inside cells (Bronshtein, 1995), and that stability of the amorphous state inside cells at low temperatures decreases with increasing mass of the  
20 protectant inside cells (Bronshtein, 1995).

#### BRIEF DESCRIPTION OF THE DRAWING

Fig. 1 shows a plot of the effect of co-solutes on toxicity of 60% ethylene glycol vitrification solution on red blood cells.

#### 25 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is directed toward improving low temperature preservation of cells, multicellular specimens and organs by vitrification. To avoid ice formation, samples should be substantially  
30 dehydrated. The dehydration damages cells because of large repulsive forces between macromolecules that occur inside cells. A small amount of protectant should be present inside cells in order to decrease these forces. However, the amount of protectant inside the cells should be kept as  
35 low as possible to decrease the toxic effect of vitrification solution and to increase the stability of the amorphous state inside the cells at low temperatures. This

can be achieved by including non-penetrating co-solutes (amino acids, betaines, sugars, etc.) in the vitrification solution in concentrations from 0.1 - 0.7 mol/l.

After preservation, the samples should be rehydrated and returned to normal physiological medium. In other words, intracellular protectant should be removed from the cells and exchanged for water. The inventor believes that damage during rehydration occurs because of an increase in cell volume to more than the initial cell volume, when cells are transferred from vitrification solution to washing (rehydration) solutions. To avoid this possibility of damage, one has to include in rehydration solutions: amino acids, betaines, carbohydrates, or other non-penetrating, co-solutes that effectively decrease the chemical potential of permeating protectants in aqueous solutions. The co-solutes are used in concentrations from 0.1 - 0.7 mol/l. Higher co-solute concentrations will more effectively limit the mass of intracellular protectant, however, when this mass gets very small the dehydrated cells may be damaged.

The method for preserving a biological sample comprising the step of loading the sample by contacting the sample with a solution comprising a permeating protectant and a co-solute that decreases the ability of the protectant to enter cells of the biological specimen. The protectant is one of a group of common permeating protectants including, but not limited to, dimethylsulfoxide, ethylene glycol, propylene glycol and glycerol. The co-solute is one of a number of the following classes of compounds including, but not limited to, amino acids and derivatives thereof soluble in water in concentration greater than 0.1 mol/l, betaines soluble in water in concentration greater than 0.1 mol/l, carbohydrates and sugar alcohols, wherein the carbohydrates are selected from the group consisting of aldose monosaccharides, ketose monosaccharides, amino sugars, alditols, inositols, aldonic, uronic and aldonic acids

soluble in water in concentrations of greater than 0.1 mol/l, disaccharides and polysaccharides. The total concentration of non-permeating co-solutes in the vitrification solution is preferably between 0.1 and 0.7 mol/l and is equal to a maximum possible concentration that does not damage cells.

The method of the present invention involves both gradual and/or stepwise loading of permeating protectants with simultaneous increase in concentration of permeating protectants and non-permeating co-solutes. The concentration of non-permeating co-solutes should be the maximum possible concentration that still does not damage the biological specimen.

Specifically, the loading step is performed in two or more stages of contacting the sample with increasingly higher concentrations of permeating protectant and co-solute. The loading step is performed by simultaneously increasing concentrations of both the protectant and the co-solute from initial concentrations to final concentrations according to a desired profile. The initial concentration of permeating protectant is zero. The initial concentration of co-solute is preferably zero, but may be greater than zero as long as the co-solute does not damage the sample. The final concentration of co-solute may be determined empirically depending on the nature of the specimen and the choice and concentration of protectant.

The unloading of the protectant can be performed in a gradual or step-wise manner. The only limitation in the profile of the simultaneous increase in protectant and co-solute concentration during loading is that the concentrations of the respective elements remain in an optimal proportion to minimize toxic effect of high concentrations of protectants. The increase in concentration of the protectant and co-solute may be performed manually or mechanically and may be accomplished stepwise or according to a desired profile. The shape of

the profile curve may be linear or non-linear, depending upon empirical optimization of the profile for a specific cell type.

Once a biological sample is preserved and stored,  
5 it eventually must be rehydrated with the aim of retaining viability of the sample. The rehydration or unloading step is directed to the replacement of protectant in the preserved sample with water. The step of unloading the sample is performed by contacting the sample with a  
10 rehydration solution which can be an aqueous solution lacking the protectant (having smaller concentration of the protectant) such that the protectant is removed from the cells of the sample. Preferably, the sample is unloaded in a manner opposite that of the loading step. Specifically,  
15 the rehydration solution includes a co-solute and a protectant and the unloading step is performed by simultaneously decreasing concentrations of both the protectant and the co-solute from initial concentrations to final concentrations according to a desired profile. The  
20 initial concentrations of both the protectant and the co-solute may be identical to or smaller than the final concentrations thereof, respectively, in the loading process. Preferably, the protectant and the co-solute used during unloading are the same as those used during loading  
25 of the same sample.

The protectant and co-solute of the rehydration or unloading solution are selected from the same groups of compounds used in the loading or vitrification solutions. The protectant is one of a group of common permeating  
30 protectants including, but not limited to, dimethylsulfoxide, ethylene glycol, propylene glycol and glycerol. The co-solute is one of a number of the following classes of compounds including, but not limited to, amino acids and derivatives thereof soluble in water in  
35 concentration greater than 0.1 mol/l, betaines soluble in water in concentration greater than 0.1 mol/l, carbohydrates and sugar alcohols, wherein the carbohydrates



are selected from the group consisting of aldose monosaccharides, ketose monosaccharides, amino sugars, alditols, inositols, aldonic, uronic and aldaric acids soluble in water in concentrations of greater than  
5 0.1 mol/l, disaccharides and polysaccharides. The total concentration of non-permeating co-solutes in the unloading solutions is preferably between 0.1 and 0.7 mol/l and is equal to a maximum possible concentration that does not damage cells.

10 As with the loading step, the unloading step involves both gradual and/or stepwise unloading of permeating protectants with a simultaneous decrease in the concentration of the permeating protectants and non-permeating co-solutes. The initial concentration of non-  
15 permeating co-solutes should be the maximum possible concentration that still does not damage the biological specimen.

Specifically, the unloading step is also performed in two or more stages of contacting the sample  
20 with increasingly lower concentrations of permeating protectant and non-permeating co-solute. The unloading step is performed by simultaneously decreasing concentrations of both the protectant and the co-solute from initial concentrations to final concentrations  
25 according to a desired profile. The initial concentrations of protectant and co-solute is preferably the same as the final concentrations in the loading (vitrification) solution. The final concentration of permeating protectant is zero. The final concentration of co-solute may be  
30 greater than zero as long as the co-solute does not damage the sample cells.

The loading of the protectant can be performed in a gradual or stepwise manner. The only limitation in the profile of the simultaneous decrease in protectant and co-  
35 solute concentrations during unloading is that the concentrations of the respective elements remain in an optimal proportion to minimize toxicity and to maximize

viability on rehydration. The decrease in concentrations of the protectant and co-solute may be performed manually or mechanically and may be accomplished stepwise or according to a desired profile. The shape of the profile  
5 curve may be linear or non-linear, depending on empirical optimization of the profile for a specific cell type.

EXAMPLE 1. Gradual Loading and Unloading of Rat Heart with Dimethylsulfoxide (DMSO).

Materials and Methods

10           *Preparation of the Cardiac explant:* The animal experiments were conducted in accordance with the "Principles of Laboratory Animal Care" formulated by the Institute of Laboratory Animal Resources and the "Guide for the Care and Use of Laboratory Animals" prepared by the  
15 Institute of Laboratory Animal Resources and published by the National Institute of Health (NIH Publication No. 86-23, 1985). Male Sprague-Dawley rats (300-350g) were anesthetized with sodium pentobarbital (65 mg/kg, ip) and anticoagulated with heparin (250u, iv). The heart was  
20 excised and immediately immersed in ice-cold Krebs-Henseleit buffer (KHB), which contained (in mM): 118 NaCl, 11 glucose, 25 NaHCO<sub>3</sub>, 4.7 KCl, 1.2 MgSO<sub>4</sub>, 1.2 KH<sub>2</sub>PO<sub>4</sub>, 0.5 Na-EDTA, and 2.5 CaCl<sub>2</sub>. The aorta was cannulated and the heart retrograde perfused at 70 mm Hg for 9 min. with  
25 36.5°C KHB equilibrated with 95% O<sub>2</sub>/5% CO<sub>2</sub>. The perfusion was continued for 2 min. at 60 mm Hg with CP-11E saturated with 100% O<sub>2</sub>. The composition of CP-11E (in mM) was: 125 NaCl, 7 glucose, 1.2 KH<sub>2</sub>PO<sub>4</sub>, 10 mannitol, 15 MgSO<sub>4</sub>, 14 KCl, 10 Hepes, 0.02 EDTA, 0.28 CaCl<sub>2</sub>, pH 7.5.

30           *Loading and removal of DMSO and mannitol:* After CP-11E flush, the arrested heart was transferred to a perfusion apparatus (Fig. 1). Both CP-11EB and CP-11E+DMSO+mannitol were bubbled constantly with 100% O<sub>2</sub>. Perfusate was delivered via an aortic cannula by a  
35 peristaltic pump at a flow rate of 1 ml/min. Two experiments were performed at room temperature.

Experiment 0: The heart was gradually loaded with 30 wt% DMSO and immediately unloaded. No co-solutes were used. A linear gradient of 0 to 30% DMSO was generated using a gradient maker. DMSO gradient was controlled by the duration of infusion (or the total volume of solution infused). Loading time was 30 min. During the 30 min. loading, the rate of increase in concentration of the solution was 1% DMSO/min. Unloading began right after the end of loading. Unloading time was 60 min. During the 60 min. unloading, a gradient of decreasing DMSO concentration was 0.5 wt%/min.

Experiment 1: The heart was gradually loaded with 30 wt% DMSO and immediately unloaded. A linear gradient of both 0 to 30% DMSO and 0 to 3% mannitol was generated using a gradient maker. DMSO gradient was controlled by the duration of infusion (or the total volume of solution infused). Loading time was 30 min. During the 30 min. loading, the rate of increase in concentration of the solution was 1% DMSO/min. and 0.075% mannitol/min. Unloading began right after the end of loading. Unloading time was 60 min. During the 60 min. unloading, a gradient of decreasing DMSO concentration was 0.5 wt%/min., the final concentration of mannitol was 1 wt%.

Experiment 2: The heart was gradually loaded with 30 wt% DMSO during 30 min, then perfused 30 min. with 30% DMSO + 3% mannitol, and then unloaded during 60 min. A linear gradient of both 0 to 30% DMSO and 0 to 3% mannitol was generated using a gradient maker. DMSO gradient was controlled by the duration of infusion (or the total volume of solution infused). During the 30 min. loading, the rate of increase in concentration was 1% DMSO/min. and 0.075% mannitol/min. During the 60 min. unloading, a gradient of decreasing DMSO concentration was 0.5 wt%/min, the final concentration of mannitol was 1 wt%.

*Assessment of cardiac function:* Cardiac function was assessed by working mode reperfusion with KHB at 11 mm Hg preload and 70 mm Hg after load. Heart rate (HR,

beats/min), aortic and coronary flow (AF and CF, ml/min.), cardiac output (CO=AF+CF, ml/min.), systolic and diastolic aortic pressure (mm Hg) were recorded. Coronary vascular resistance and work were calculated according to Neely et al., 1967 (Neely et al. "Effect of Pressure Development on Oxygen Consumption by the Isolated Rat Heart". *Am. J. Physiology*, 212:804-12, 1967).

Results: When mannitol was not present during DMSO loading and unloading (Experiment 0), the heart developed contracture and showed no recovery in function after unloading. With mannitol present during loading, perfusion and unloading, hearts remained soft and recovered substantial function after unloading. Table I shows the recovered cardiac function after DMSO unloading. The results clearly demonstrated that the presence of mannitol prevented damage to the heart caused by exposure to both high concentration of DMSO and extreme changes in extracellular osmotic pressure during loading and unloading.

#### EXAMPLE 2: Step Loading and Unloading of Rat Blood with Ethylene Glycol (EG)

##### Materials and Methods

Blood was sampled from external jugular vein of rats after heart extrusion described in Example 1.

##### Step loading:

Step 1: 100  $\mu$ l of blood were mixed with 100  $\mu$ l of 30 wt% EG + 0.9 wt% NaCl. Equilibration time 10 min.

Step 2: 1000  $\mu$ l of vitrification solution containing mixture of 60 wt% EG + 0.9 wt% NaCl with different amounts of glutamic acid monosodium Salt (GA) per gram of Vitrification solution were slowly (during 3-5 min.) added to the mixture obtained after Step 1.

After that the blood cells were equilibrated in Vitrification solution during 60 min. before unloading.

*Step unloading*

Step 1: After 60 min. equilibration in vitrification solution erythrocytes were centrifuged down (5 min. at 2000g), 0.5 ml of supernatant was removed from  
5 each sample, and 0.5 ml of 3 wt% GA + 0.9 wt% NaCl were added to each sample. Then the samples were mixed by vortexing and equilibrated 10 min.

Step 2: After 10 min. of equilibration, above the erythrocytes were centrifuged down again, then, 0.5 ml  
10 of supernatant was removed from each sample, and 0.5 ml of 3 wt% GA + 0.9 wt% NaCl were added to each sample. Then the samples were mixed by vortexing and were equilibrated 10 min.

Then erythrocytes were centrifuged down again and  
15 0.5 ml of supernatant was collected from each sample.

Concentration of free hemoglobin in supernatants collected from the samples after equilibration in Vitrification solution, first and second step of unloading was used to characterize the erythrocyte damage  
20 (hemolysis). The concentration of free hemoglobin was measured using 390 Turner spectrophotometer (at 550nm wavelength) after adding 0.5 ml of supernatant to 3 ml of water. The hemolysis was measured as a ratio of hemoglobin concentration in the supernatants to the hemoglobin  
25 concentration in the mixture of 41.7  $\mu$ l of blood with 3.5 ml water that was taken as 100% hemolysis.

The experiment was performed at room temperature. pH of all solutions used in the experiment was 7.0

Results: The dependencies of hemolysis on  
30 concentration of GA in vitrification solution after equilibration (solid lines), first (dashed lines) and second step of unloading (dashed - dotted lines) are shown in Fig. 1. From the results presented in Fig.1, it is seen that addition of co-solutes (GA) protects erythrocytes from  
35 damage in Vitrification solution. However, as it was said in the patent description above, the too high concentration of co-solutes may be also damaging.

Table 1. The effects of DMSO loading and removal in the presence of mannitol on the function of the isolated rat heart. Control heart function was established by perfusing freshly isolated hearts in working mode for 30 min. Function of DMSO-treated hearts was expressed in real numbers. Recovery was expressed as percentage of control function and shown in parentheses.

Exper. Number	n	HR	AF	CF	CO	SP	DP	WORK	CVR
1	1	260 (94%)	42.9 (84%)	14.4 (59%)	57.3 (76%)	119 (90%)	73 (118%)	68.8 (81%)	5.07 (193%)
2	1	289 (104%)	22.5 (44%)	21 (86%)	43.5 (58%)	96 (72%)	58 (94%)	41.8 (49%)	2.76 (105%)
Control	8	276 ±18	51.1 ±2.5	24.5 ±1.3	75.6 ±3.0	133 ±2	62 ±3	85.0 ±5.4	2.64 ±0.20

## References

- Bronshtein, V.L. 1995. A heresay about an organ cryopreservation by vitrification. In: "Cryo'95 program", Abstract P2-66 of a Paper Presented at the 32nd Annual Meeting of the Society for Cryobiology, Madison, Wisconsin.
- 5 Bronshtein, V.L. 1995. Binding, of protectants to the biological macromolecules. In: "Cryo'95 program", Abstract P2-65 of a Paper Presented at the 32nd Annual Meeting of the Society for Cryobiology, Madison, Wisconsin.
- Bronshteyn, V.L. and Steponkus, P.L. 1994. Amino acids and  
10 carbohydrates limit permeation of ethylene glycol in *Drosophila melanogaster* embryos. In: "Abstract of Papers Presented at the 31st Annual Meeting of the Society for Cryobiology", Abstract 54, Kyoto, Japan.
- Bronshteyn, V.L. and Steponkus, P.L. 1993. Differential  
15 scanning calorimeter studies of heterogeneous ice nucleation in *Drosophila melanogaster* embryos. In: "Abstract of Papers Presented at the 30th Annual Meeting of the Society for Cryobiology", Abstract 22, Atlanta, Georgia.
- 20 Bronshteyn, V.L. and Steponkus, P.L. 1992. Differential scanning calorimeter studies of ice formation in *Drosophila melanogaster* embryos. *Cryobiology* 29:764-765. (Abstract)
- Bryant, G. and Wolfe, J. Interfacial forces in cryobiology and anhydrobiology. *Cryo-Letters* 13, 23-36, 1992.
- 25 Crowe, J.H., Carpenter, J.F., Crowe, L.M. and Anchorodoguy, T.J. (1990). Are freezing and dehydration similar stress vectors? A comparison of modes of interaction of stabilizing solutes with biomolecules, *Cryobiology* 27: 219-231.

- Fahy, G.M., Lilley, T.H., Linsdell, H., St. John Douglas M. and Meryman, H.T. 1990. Protectant toxicity and protectant toxicity reduction: In search of molecular mechanisms. *Cryobiology* 27:247-268.
- 5 Fahy, G.M., MacFarlane, D.R., Angell, C.A. and Meryman, H.T. 1984. Vitrification as an approach to cryopreservation. *Cryobiology* 21:407-426.
- Gekko, K. and Timasheff, S.N. 1981. Mechanism of stabilization by glycerol: Preferential hydration in  
10 glycerol-water mixtures. *Biochemistry* 20: 4667-76.
- Langis, R. and Steponkus, P.L. 1990. Cryopreservation of rye protoplasts by vitrification. *Plant Physiol.* 92:666-671.
- Lee, J.C. and Timasheff, S.N. (1981) The stabilization of  
15 proteins by sucrose. *J. Biol. Chem.* 256: 7193-7201
- Kasai, M., Komi, J.H., Takakamo, A., Tsudera, H., Sakurai, T. and Machida, T. 1990. A simple method for mouse embryo cryopreservation in a low toxicity vitrification solution, without appreciable loss of viability. *J. Reprod. Fertil.*  
20 89:91-97.
- Kedem, O. and Katchalsky, A. (1958) Thermodynamic analysis of the permeability of biological membranes to non-electrolytes. *Biochem. Biophys. Acta* 27:229-246.
- Meryman, H.T. 1967. The relationship between dehydration  
25 and freezing injury in the human, erythrocyte. In: *Cellular Injury and Resistance in Freezing Organisms*. Vol. II, edited by E. Asahina. pp. 231-244. Institute of Low Temperature Science, Hokkaido University, Sapporo, Japan.



- Meryman, H.T. 1970. The exceeding of a minimum tolerable cell volume in hypertonic suspension as a cause of freezing injury. In: *The Frozen Cell*, edited by G.E.W. Wolstenholme and M. O'Conner. pp. 51-67. J. & A. Churchill, London.
- 5 Rall, W.F. and Fahy, G.M. 1985a. Vitrification: A new approach to embryo cryopreservation. *Theriogenology* 23:220.
- Rall, W.F. and Fahy, G.M. 1985b. Ice-free cryopreservation of mouse embryos at -196°C by vitrification. *Nature*  
10 313:573-575.
- Steponkus, P.L., Bronshteyn, V.L. and Caldwell, Sh. 1994. Cryopreservation of *Drosophila melanogaster* embryos: Formulation of improved vitrification solutions. In: "Abstract of Papers Presented at the 31st Annual Meeting  
15 tcDr of the Society for Cryobiology", Abstract 51, Kyoto, Japan.
- Steponkus, P.L., Langis, R. and Fujikawa, S. 1992. Cryopreservation of plant tissues by vitrification. In: *Advances in Low-Temperature Biology*, Vol. 1, edited by P.L. Steponkus. pp. 1-61. JAI Press, Ltd., London.  
20
- Tachikawa, S., Otoi, T., Kondo, S., Machida, T. and Kasai, M. 1993. Successful vitrification of bovine blastocysts, derived by *in vitro* maturation and fertilization. *Mol. Reprod. Dev.* 34:266-271.
- 25 Timasheff, S.N. 1993. The control of protein stability and association by weak interaction with water: How do solvents affect these processes? *Annu. Rev. Biophys. Biolmol. Strict.* 22: 67-97.

Zhu, S.E., Kasai, M., Otoge, H., Sakurai, T. and Machida, T. 1993. Cryopreservation of expanded mouse blastocysts by vitrification in ethylene glycol-based solutions. *J. Reprod. Fertil.* 98:139-145.

I Claim:

1. A method for preserving a biological sample, comprising the step of loading the sample with permeating protectants by contacting the sample with a solution  
5 comprising a permeating protectant and a non-permeating co-solute that limits the amount the protectant penetrates into the cells of the biological sample.
2. The method for preserving a biological sample as claimed in claim 1, further comprising the step of unloading the sample by contacting the sample with a rehydration solution comprising a solution lacking the  
5 protectant such that the protectant is removed from the cells of the sample.
3. The method for preserving a biological sample, as claimed in claim 1 wherein the protectant is selected from the group consisting of dimethylsulfoxide, ethylene glycol, propylene glycol and glycerol.
4. The method for preserving a biological sample as claimed in claim 1, wherein the co-solute is selected from the group consisting of an amino acid and derivatives thereof soluble in water in concentration  
5 greater than 0.1 mol/l, a betaine soluble in water in concentration greater than 0.1 mol/l, a carbohydrate and a sugar alcohol, wherein the carbohydrate is selected from the group consisting of an aldose monosaccharide, a ketose monosaccharide, an amino sugar, an alditol, an inositol,  
10 aidonic, uronic and aldarcic acids soluble in water in concentrations of greater than 0.1 mol/l, disaccharides and polysaccharides.
5. The method for preserving a biological sample as claimed in claim 1, wherein the total concentration of non-permeating co-solutes in the

vitrification solution is between 0.1 and 0.7 mol/l and is equal to a maximum possible concentration that does not substantially damage cells.

6. The method for preserving a biological sample as claimed in claim 4, wherein the co-solute is an amino acid.

7. The method for preserving a biological sample as claimed in claim 1, wherein the loading step is performed in two or more stages of contacting the sample with simultaneously increasing concentrations of the  
5 protectant and the co-solute.

8. The method for preserving a biological sample as claimed in claim 1, wherein the loading step is performed by simultaneously increasing concentrations of both the protectant and the co-solute from initial  
5 concentrations to final concentrations according to a desired profile.

9. The method for preserving a biological sample as claimed in claim 1, further comprising the step of unloading the sample by contacting the sample with a rehydration solution comprising a non-permeating co-solute  
5 and a permeating protectant, the unloading step is performed gradually or stepwise by simultaneously decreasing concentrations of both the protectant and the co-solute according to a desired profile.

10. The method for preserving a biological sample as claimed in claim 9, wherein the co-solute is selected from the group consisting of an amino acid and derivatives thereof soluble in water in concentration  
5 greater than 0.1 mol/l, a betaine soluble in water in concentration greater than 0.1 mol/l, a carbohydrate and a sugar alcohol, wherein the carbohydrate is selected from

the group consisting of an aldose monosaccharide, a ketose monosaccharide, an amino sugar, an alditol, an inositol, aidonic, uronic and aldarcic acids soluble in water in concentrations of greater than 0.1 mol/l, disaccharides and polysaccharides.

11. The method for preserving a biological sample as claimed in claim 1, wherein the loading step is performed at room temperature or higher.

12. A cryopreservation solution for use in cryopreserving biological samples comprising a protectant and a co-solute.

13. The cryopreservation solution as claimed in claim 12, wherein the protectant is selected from the group consisting of dimethylsulfoxide, ethylene glycol, propylene glycol and glycerol.

14. The cryopreservation solution as claimed in claim 12, wherein the co-solute is selected from the group consisting of an amino acid and derivatives thereof soluble in water in concentration greater than 0.1 mol/l, a betaine soluble in water in concentration greater than 0.1 mol/l, a carbohydrate and a sugar alcohol, wherein the carbohydrate is selected from the group consisting of an aldose monosaccharide, a ketose monosaccharide, an amino sugar, an alditol, an inositol, aidonic, uronic and aldarcic acids soluble in water in concentrations of greater than 0.1 mol/l, disaccharides and polysaccharides.

15. A rehydration solution for use in rehydrating cryopreserved biological samples comprising a protectant and a co-solute.

16. The rehydration solution as claimed in claim 15, wherein the protectant is selected from the group

consisting of dimethylsulfoxide, ethylene glycol, propylene glycol and glycerol.

17. The rehydration solution as claimed in claim 15, wherein the co-solute is selected from the group consisting of an amino acid and derivatives thereof soluble in water in concentration greater than 0.1 mol/l, a betaine  
5 soluble in water in concentration greater than 0.1 mol/l, a carbohydrate and a sugar alcohol, wherein the carbohydrate is selected from the group consisting of an aldose monosaccharide, a ketose monosaccharide, an amino sugar, an alditol, an inositol, aldonic, uronic and aldaric  
10 acids soluble in water in concentrations of greater than 0.1 mol/l, disaccharides and polysaccharides.

18. The rehydration solution according to claim 17, wherein the concentration of the co-solute has a maximum value that does not damage the sample at room or subzero temperatures.

1/1




FIG. 1

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/09207

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A01N 1/00, 1/02

US CL : 435/1.3, 2

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/1.3, 2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Biosis

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 4,980,277 A (JUNNILA) 25 December 1990, column 3, lines 56-66.	1, 3-6, 8, 11-18 ----- 1-18
X --- Y	US 5,071,741 A (BROCKBANK) 10 December 1991, column 4, lines 40-55, column 5, lines 6-50, column 6, lines 47-60 and abstract.	1-5, 7-10, 12-18 ----- 1-18
Y, P	US 5,595,866 A (CRITSER et al.) 21 January 1997, see abstract.	1-11



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

02 SEPTEMBER 1997

Date of mailing of the international search report

24 SEP 1997

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Sandra Saucier

Telephone No. (703) 308-0196



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/09207

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☒ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/09207

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-11, drawn to a method of preserving a biological sample comprising loading the sample with a solution comprising a permeating protectant and a non-permeating protectant.

Group II, claim 12-18, drawn to a solution comprising a protectant and a co-solute.

and it considers that the International Application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated below:

The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The solution of group II comprises a protectant and a co-solute. This solution is not required for the practice of the method of Group I which requires a solution comprising a permeating protectant and a non-permeating protectant. Further, the solution, as claimed is not an improvement over the prior art because Junnila (US 4,980,277) discloses a solution comprising a protectant, such as glycerol in a cosolvent such as distilled water (see claims). Accordingly, the solution does not constitute a special technical feature as defined by PCT Rule 13.2.